알아보기
While We Wait for AIM Therapy: Nutraceutical Care for Cats with Kidney Disease
< Three-sentence Summary >
- Oxidative stress, chronic inflammation, and uremic toxin accumulation in CKD continuously burden the kidneys and reinforce one another in a self-perpetuating cycle.
- Resveratrol, CoQ10, quercetin, curcumin, probiotics, and prebiotics are among the best-studied nutraceutical compounds in relation to these pathological pathways.
- Greycoat Research proposes a practical nutritional management approach for cats with CKD - grounded in AIM research and feline CKD pathophysiology - as a meaningful option for cat owners while waiting for the treatment to become available.
< Introduction >
The first two posts in this series established that feline CKD involves a functional defect in AIM (Apoptosis Inhibitor of Macrophage - a circulating protein that tags cellular waste for removal by immune cells) and that some cats may carry a genetic variant that compounds this problem. A regulatory approval application for rAIM therapy has been submitted in Japan.
But the treatment is not yet in our hands, and time continues to pass. What can we do as cat owners in the meantime?
This post reviews which nutraceutical compounds have evidence supporting a role in CKD management, and what that evidence actually says.
< Background: What is a Nutraceutical? >
Before going further, one term that appears throughout this post is worth defining: nutraceutical.
The word is a portmanteau of ‘Nutrition’ and ‘Pharmaceutical’, coined by Dr. DeFelice in 1989. It refers to any substance derived from food sources that provides health benefits beyond basic nutrition - including potential roles in disease prevention or health maintenance.
Nutraceuticals are not drugs. They do not treat specific diseases through direct pharmacological action. But they are not ordinary food either - they are compounds with identifiable biological mechanisms that can be described and studied. Resveratrol, CoQ10, curcumin, quercetin, probiotics: all of these fall under the nutraceutical umbrella.
Think of them as sitting somewhere between food and medicine. Throughout this post, ‘supplement’ and ‘nutraceutical’ are used interchangeably to refer to these compounds.
< Background: Why Does CKD Progress? >
Before discussing specific compounds, it helps to understand what drives CKD progression beyond simple nephron loss. Three interconnected processes form a self-reinforcing cycle.
1. Oxidative stress
The kidneys consume enormous energy to filter blood continuously. When renal tissue is damaged, the efficiency of this filtration process declines - and alongside accumulating waste, ROS (Reactive Oxygen Species - unstable, highly reactive molecules) build up in excess. These remaining ROS damage tubular cells again, amplify inflammation, and accelerate fibrosis (the hardening of renal tissue into scar-like structures), initiating a vicious cycle.
2. Chronic inflammation
Cats with CKD show persistently elevated levels of SAA (Serum Amyloid A - discussed in the first post) and other inflammatory proteins. This sustained low-grade inflammation continuously irritates renal tissue, replacing functional cells with fibrotic tissue.
3. Uremic toxin accumulation
As GFR (Glomerular Filtration Rate - the measure of how efficiently the kidneys filter blood) declines, creatinine, BUN (Blood Urea Nitrogen), and IS (Indoxyl Sulfate - a gut-derived toxin produced when intestinal bacteria metabolize tryptophan, an essential amino acid) accumulate in the bloodstream. IS in particular directly damages tubular cells and amplifies systemic inflammation.
These three processes reinforce one another. Nutritional management is a realistic approach to addressing the internal environment in which this cycle operates.
< The Papers >
This post draws on two reviews.
The first is a 2021 review by a Polish medical university team, broadly covering how various nutraceutical compounds have been studied in CKD - covering resveratrol, CoQ10, quercetin, curcumin, and gut microbiota-modulating agents. (https://www.mdpi.com/1999-4923/13/2/231)
The second one is a narrative review from an Indian research team synthesizing findings from 19 studies on nutraceutical compounds in early-stage CKD. (https://www.cureus.com/articles/266138-exploring-the-renoprotective-potential-of-bioactive-nutraceuticals-in-chronic-kidney-disease-progression-a-narrative-review#!/)
< Resveratrol: Cellular Aging and Antioxidant Pathways >
Resveratrol is a polyphenol (a class of plant-derived antioxidant compounds) naturally found in certain plants, including grapes and berries. It has attracted attention for its antioxidant, anti-inflammatory, and anti-aging properties - particularly its ability to activate the sirtuins (SIRT - a protein family that regulates cellular aging, DNA repair, and energy metabolism) pathway.
The papers report that resveratrol attenuated oxidative stress pathways in the kidney, improved blood flow within the glomerulus (the kidney’s primary filtration structure), and slowed renal fibrosis in preclinical models. In a clinical trial, 40 mg/day resveratrol for six weeks significantly reduced the inflammatory cytokine TNF-α (Tumor Necrosis Factor-alpha) and the inflammatory proteins IL-6 and CRP (C-Reactive Protein) in human subjects.
< CoQ10: Mitochondrial Support >
CoQ10 (Coenzyme Q10) is essential for ATP (Adenosine triphosphate = the cell’s primary energy currency) production in mitochondria (the cell’s energy-generating organelle). CKD patients frequently show reduced CoQ10 levels, which is considered one factor amplifying oxidative stress.
The papers report that CoQ10 supplementation lowered oxidative stress markers and stabilized kidney function indices in CKD patients. In a 12-week RCT (Randomized Controlled Trial) in diabetic nephropathy (diabetic kidney disease) patients, 100 mg/day CoQ10 significantly reduced insulin resistance (the state in which insulin fails to function properly), MDA (malondialdehyde - an oxidative stress marker), and AGE (Advanced Glycation End-products - harmful compounds formed by sugar-protein binding).
Direct feline clinical data remain limited. The mechanistic findings from human and rodent studies can serve as a reference, but applying them to cats requires veterinary judgement and consideration of individual patient status.
< Quercetin: Antioxidant and Anti-inflammatory Pathways >
Quercetin is a flavonoid (a broad class of plant-derived antioxidant compounds) found abundantly in onions and apples.
Multiple studies have confirmed that quercetin suppresses oxidative stress and inflammatory responses in renal tissue at the preclinical stage. It has also been frequently reported to improve renal blood flow and protect GFR. Its simultaneous engagement of multiple CKD-relevant pathways has led to its classification as a ‘multi-mechanistic compound’.
< Curcumin: Anti-inflammatory and Anti-fibrotic Pathways >
Curcumin, the primary bioactive compound in turmeric, has long been recognized for its anti-inflammatory properties. In the context of CKD, it has more recently attracted attention for its ability to suppress renal fibrosis (the progressive hardening of kidney tissue).
The papers report that curcumin inhibits the NF-κB (Nuclear Factor kappa B - a master regulator of inflammatory gene expression) pathway, reducing pro-inflammatory cytokine (signaling protein) production and slowing fibrotic remodeling. In a clinical trial of 40 diabetic nephropathy patients, two months of curcumin supplementation significantly reduced TGF-β (Transforming Growth Factor-beta - a key driver of fibrosis), IL-8 (Interleukin-8 - a pro-inflammatory cytokine), and proteinuria (abnormal protein loss in urine).
Curcumin has notoriously poor bioavailability (the proportion of an ingested compound that actually reaches systemic circulation), which is why formulation approaches such as piperine (black pepper extract) combination or phytosome (a phospholipid-bound form that improves absorption) are actively being developed.
(This is why our formula uses curcumin phytosome rather than standard curcumin).
< Gut Environment: Probiotics and Prebiotics >
The relationship between CKD and gut health has attracted considerable research attention, described as the ‘gut-kidney axis’ (the bidirectional communication pathway between intestinal microbiota and kidney function).
As renal function declines, large amounts of urea are secreted into the digestive tract, altering the composition of gut microbiome (the microbial community inhabiting the intestine). Proteolytic (protein-degrading) bacteria increase, generating more uremic toxins such as IS. These toxins are absorbed into the bloodstream and damage the kidneys again, forming a vicious cycle. Simultaneously, increased gut mucosal permeability (the degree to which substances pass through the intestinal lining) allows LPS (lipopolysaccharide - a bacterial cell wall component) to enter systemic circulation and drive systemic inflammation.
Multiple studies report that probiotics (beneficial bacteria that positively influence the gut environment) and prebiotics (dietary fibers that serve as food for beneficial bacteria) normalize gut microbial composition and reduce uremic toxin production.
In the first post in this series, rAIM administration was associated with reduced LPS-binding protein (LPS-BP) levels - a finding consistent with the gut-kidney axis playing a meaningful role in CKD progression.
< Limitations and Caveats >
Both papers acknowledge the following limitations.
1. Limited direct feline evidence
Most studies are based on preclinical rodent models and human clinical trials. Cats differ metabolically from omnivores such as humans and rodents, so applying these findings to cats without additional validation requires caution.
2. Short study durations
Most clinical trials cover weeks to a few months. Long-term efficacy and safety data are lacking.
3. Bioavailability
Some compounds have limited oral absorption. Formulation choices, such as phytosomal, liposomal, or nanoparticle-based delivery, can matter as much as the choice of compound itself.
4. Drug interactions
When multiple compounds are used together or alongside existing medications, potential interactions must be considered.
< Conclusion >
Nutraceuticals should be understood not as a treatment, but as part of daily care that helps support a healthier internal environment. Placing uncritical faith in supplements as a cure is dangerous.
At the same time, dismissing nutraceuticals without engaging with the evidence is not the right position either. As this post has shown, resveratrol, CoQ10, quercetin, curcumin, and probiotics each have scientific evidence linking them to the core pathological axes of CKD: oxidative stress, chronic inflammation, and uremic toxin accumulation. The limitation of restricted feline-specific data is real, but the shared pathological mechanisms across species make it difficult to dismiss these compounds entirely.
The realistic approach available to us now is neither uncritical belief nor blanket dismissal, but beginning evidence-based, appropriate management. Rather than arbitrarily dividing human supplements for cats or making independent dosing decisions, it is important to consider the cat’s current condition alongside veterinary judgement. While waiting for the AIM treatment, there are already meaningful steps that can be taken to support feline kidney health in daily life.
< Personal Thoughts >
The time before rAIM therapy becomes available does not have to be passive waiting. It is an opportunity to monitor and manage our cats’ internal environment consistently. The choice between doing nothing and starting evidence-based nutritional management is a real and meaningful one.
Oxidative stress, chronic inflammation, uremic toxin accumulation, and gut dysbiosis - the key themes running through this post - are consistently identified across the literature as central management targets in CKD. Resveratrol, CoQ10, quercetin, curcumin, probiotics, and prebiotics are the compounds most extensively studied in relation to these targets. This is why Greycoat Research focuses on the nutraceutical approach: not to replace medicine, but to build a daily management option that cat owners can sustain.
One important caveat. Compounds studied in humans or rodents cannot simply be transposed to cats. Cats are obligate carnivores with distinct metabolic pathways, different essential amino acid requirements, and different nutritional physiology. Feline nutritional management is not about adding whatever is trending - it requires integrating the cat’s biology with the known pathological mechanisms of CKD.
Greycoat Research approaches this from that angle: examining both the cross-species mechanisms (oxidative stress, inflammation, gut-kidney axis) and the cat-specific factors (AIM biology, obligate carnivore metabolism, feline amino acid requirements) to design a nutritional management approach built for cats, not adapted from human formulas.
While waiting for the treatment, the options available to cat owners include regular monitoring, dietary management, hydration support, and targeted nutritional supplementation. If you are unsure which compounds are appropriate for your cat, consult your veterinarian or a Greycoat Research specialist to explore a nutrition plan suited to your cat’s current condition.
About the AuthorHocheol Shin, Ph. D.
|
[Past articles]
1. Dr. Toru Miyazaki’s AIM Therapy for Feline CKD
2. Could My Cat Have an AIM Mutation That Accelerates Kidney Disease Progression?